1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Robert Haddad, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma 9-ING-41, Carboplatin, Pembrolizumab - Salivary Gland Cancer, Recurrent Salivary Gland Cancer | Phase 2 | Active not recruiting | Robert Haddad, MD | 32 | 2021-09-17 | 2026-10-23 |
Carcinoma, Adenoid Cystic (1) · Neoplasm Metastasis (1) · Salivary Gland Neoplasms (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Carboplatin (1) · pembrolizumab (1)
United States (1)